Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056758 · ClinicalTrials.gov registry record · Phase 1
HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00056758 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 18 participants.
The verdict
NCT00056758, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will evaluate the safety of and immune responses to a dendritic cell vaccination for HIV-1 infection. The vaccine will be made from a patient's own cells combined with small fragments of HIV-1 (made synthetically in a laboratory). These cells will be administered back to the patient either into a vein (intravenously) or the skin (subcutaneously).
Interventions
- BIOLOGICAL Autologous Dendritic Cell HIV Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056758
The ClinicalTrials.gov registry entry for NCT00056758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous Dendritic Cell HIV Vaccination is the first listed.
NCT00056758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056758 about?
NCT00056758 is a clinical study titled "HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs". This study will evaluate the safety of and immune responses to a dendritic cell vaccination for HIV-1 infection. The vaccine will be made from a patient's own cells combined with small fragments of HIV-1 (made synthetically in a laboratory). These cells will be administered back to the patient eithe...
What is the current status of trial NCT00056758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-02.
What interventions are being tested in trial NCT00056758?
The interventions under investigation include: Autologous Dendritic Cell HIV Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT00056758?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.